|1.||Arnold, Susanne M: 1 article (02/2012)|
|2.||Wang-Gillam, Andrea: 1 article (02/2012)|
|3.||Wang, Kenneth K: 1 article (02/2012)|
|4.||Gauthier, Eric: 1 article (02/2012)|
|5.||Rothenberg, Mace L: 1 article (02/2012)|
|6.||Cooper, Wendy: 1 article (02/2012)|
|7.||Lockhart, A Craig: 1 article (02/2012)|
|8.||Bukowski, Ronald M: 1 article (02/2012)|
|9.||Ayral-Kaloustian, Semiramis: 1 article (04/2008)|
|10.||Vitale, Danielle: 1 article (04/2008)|
02/01/2012 - "Using an accelerated dose escalation design, patients with refractory solid tumors were enrolled in this study and treated with TTI-237 intravenously on days 1, 8 and 15 of a 28-day cycle. "
02/01/2012 - "A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors."
02/01/2012 - "This study was to determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic profile of TTI-237, a novel anti-tubulin drug, administered weekly in patients with refractory solid tumors. "
04/01/2008 - "TTI-237 was active in vivo in several nude mouse xenograft models of human cancer, including LoVo human colon carcinoma and U87-MG human glioblastoma, when dosed i.v. or p.o. "
04/01/2008 - "When applied to cultured human tumor cells at concentrations near its IC(50) value for cytotoxicity (34 nmol/L), TTI-237 induced multiple spindle poles and multinuclear cells, as did paclitaxel, but not vincristine or colchicine. "
|2.||Glioblastoma (Glioblastoma Multiforme)
|1.||Heterologous Transplantation (Xenotransplantation)